Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over

J Cyst Fibros. 2022 May;21(3):e173-e175. doi: 10.1016/j.jcf.2022.02.009. Epub 2022 Feb 16.
No abstract available

Keywords: Adverse reactions; Covid-19; Cystic fibrosis; SARS-CoV-2; Safety; Vaccine.

Publication types

  • Letter

MeSH terms

  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Cystic Fibrosis*
  • Humans
  • RNA, Messenger
  • SARS-CoV-2
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • mRNA Vaccines